Triple therapy (n = 74) | Monotherapy (n = 72) | p-value | |
---|---|---|---|
Receiving darunavir/ritonavir. N (%) | 19 (26) | 27 (37.5) | 0.124 |
Receiving abacavir. N (%) | 12 (16.2) | NA | |
Receiving tenofovir. N (%) | 60 (81.0) | NA | |
Receiving zidovudine. N (%) | 2 (2.7) | NA | |
Receiving lamivudine. N (%) | 20 (27.0) | NA | |
Receiving emtricitabine. N (%) | 54 (72.9) | NA | |
Male. N (%) | 52 (70.3) | 52 (72.2) | 0.794 |
Age. Median (IQR) | 44 (40–48) | 47 (44–51) | 0.002 |
Prior medical disease*. N (%) | 27 (36.5) | 36 (50) | 0.099 |
Hepatitis C active. N (%) | 18 (24.3) | 14 (19.4) | 0.932 |
AIDS. N (%) | 47 (63.5) | 44 (61.1) | 0.764 |
CD4 nadir (cells/μL). Median (IQR) | 141 (47–244) | 172 (53–268) | 0.376 |
Current CD4 (cells/μL). Median (IQR) | 576 (417–805) | 623 (457–834) | 0.225 |
Years virologically suppressed. | |||
Median (IQR) | 4.7 (2.9–8.9) | 7.1 (4.5–8.9) | 0.019 |
Monotherapy | NA | 2.6 (1.9–3.9) | |
Patients with a single blip **. N (%) | 8 (10.8) | 4 (5.5) | 0.249 |
Detectable HIV RNA (Ultrasensitive assay). N (%) | 33 (44.6) | 28 (38.9) | 0.484 |
HIV RNA 20–49 copies/ml. N (%) | 12 (16.2) | 5 (6.9) | 0.081 |
Triglycerides (mg/dL). Median (IQR) | 149 (111–196) | 189 (137–248) | 0.007 |
LDL Cholesterol. Median (IQR) | 125 (107–153) | 132 (110–156) | 0.161 |
Total Cholesterol/HDL ratio. Median (IQR) | 3.8 (3.3–4.7) | 4.6 (3.7–5.6) | 0.003 |
Total Cholesterol/LDL ratio. Median (IQR) | 1.6 (1.5–1.8) | 1.6 (1.5–1.8) | 0.668 |
Receiving statins. N (%) | 17 (25.4) | 16 (24) | 0.484 |
HOMA index. Median (IQR) | 1.7 (1.0–2.7) | 2.1 (1.3–3.4) | 0.105 |
CRP level(mg/L).Median (IQR) | 0.9 (0–2.4) | 1.3 (0–2.8) | 0.478 |
CRP ≥5 mg/L. N (%) | 5 (6.8) | 10 (14.5) | 0.139 |
IL-6 (pg/ml). | |||
Median(IQR) | 1.9 (1.2–3.4) | 1.7 (1.3–3) | 0.504 |
IL-6 ≥ 3 pg/ml. N (%) | 17 (23) | 18 (25) | 0.774 |
Fibrinogen (mg/dl). Median (IQR) | 386 (351–452) | 398 (362–447) | 0.372 |
D-dimer (ng/ml). Median (IQR) | 131 (99–214) | 137 (99–234) | 0.769 |